Stock BDSX BIODESIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Biodesix, Inc.

Equities

BDSX

US09075X1081

Real-time Estimate Cboe BZX
Other stock markets
 01:45:18 2024-07-16 pm EDT 		5-day change 1st Jan Change
1.735 USD +0.87% Intraday chart for Biodesix, Inc. +7.10% -5.71%
Jul. 05 Certain Common Stock of Biodesix, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2024. CI
May. 21 Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Certain Common Stock of Biodesix, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2024.
CI
Biodesix Named to Inc. Magazine's 2024 Best Workplaces
AQ
Biodesix Named to Inc. Magazine’s 2024 “Best Workplaces”
BU
Biodesix to Participate in Two Investor Conferences in June
BU
Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
AQ
Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting
BU
Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
CI
TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target
MT
Transcript : Biodesix, Inc., Q1 2024 Earnings Call, May 08, 2024
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (BDSX) BIODESIX Reports Q1 Revenue $14.8M, vs. Street Est of $14.2M
MT
Biodesix, Inc. Reports Unaudited Impairment Charges for the First Quarter Ended March 31, 2024
CI
Biodesix, Inc. Reaffirms Revenue Guidance for the Full Year 2024
CI
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
BU
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
BU
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
BU
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
BU
Biodesix, Inc. announced that it has received $34.999422 million in funding
CI
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
AQ
Top Midday Decliners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BDSX Stock
  4. News Biodesix, Inc.